FDA Clears New Blood Test that Could Speed Alzheimer’s Diagnosis and Treatment

Health & LifestyleNews
130

Listen to article (english)

Translate to Spanish or other 102 languages!

With Alzheimer’s rates climbing and diagnoses often delayed until symptoms progress, a new FDA-cleared blood test could mark a turning point in how the disease is identified and managed. Image for illustration purposes
With Alzheimer’s rates climbing and diagnoses often delayed until symptoms progress, a new FDA-cleared blood test could mark a turning point in how the disease is identified and managed. Image for illustration purposes

Mega Doctor News

- Advertisement -

By George Washington University

Newswise – With Alzheimer’s rates climbing and diagnoses often delayed until symptoms progress, a new FDA-cleared blood test could mark a turning point in how the disease is identified and managed.

This week, the FDA cleared Roche’s Elecsys pTau181 test — only the second blood-based biomarker test approved this year for Alzheimer’s disease. The test, developed with Eli Lilly, gives primary care physicians a faster way to help rule out Alzheimer’s in patients showing signs of cognitive decline, potentially reducing reliance on costly PET scans and getting patients to answers — and treatment — sooner.

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
HHSC Encourages Preventive Care During Breast Cancer Awareness Month
Next article
STHS Children’s Partners with Spirit Halloween for Pre-Halloween Party for Patients

More Articles

Mayo Clinic Q&A: Heartburn or heart attack? How to tell the difference

Many people worry that heartburn-like symptoms could be a heart attack — and that concern is understandable.

AI-Powered Blood Test Successfully Detects Liver Cancer

Researchers at the Johns Hopkins Kimmel Cancer Center validated an artificial intelligence (AI)-powered blood test that accurately detected liver cancer in people from two geographically and biologically distinct populations and also uncovered the underlying biological signals that make the test effective.

STC Names Nurse Educator Teena Jacob 2026 Faculty of the Year

For South Texas College faculty member Teena Jacob, DNP, teaching is another form of caregiving. She approaches her students with the same compassion, patience and attentiveness that have defined her career as a nurse, helping them grow into confident, skilled healthcare professionals.

Updated Level IV Trauma Center Standards Announced by ACS

The American College of Surgeons Committee on Trauma (ACS COT) has released new standards for Level IV trauma centers. The new resource, Resources for Optimal Care of the Injured Patient: Level IV Trauma Center Standards (2026), can help Level IV trauma centers assess capabilities, identify improvement opportunities, and strengthen trauma care delivery. 
- Advertisement -